Human breast cancer MDA-mb-231 cell proliferation inhibitor
Patent Information
- Application Number
- PCT/JP2024/037697
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-05
- Filing Date
- 2024-10-23
- Publication Date
- 2025-10-02
AI Technical Summary
Current treatments for bone metastasis in breast cancer, such as bisphosphonates and chemotherapy, are associated with severe side effects, and there is a need for more effective compounds with fewer adverse effects on normal tissues.
The use of 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA), a phenolic antioxidant, to inhibit the proliferation and metastatic activity of human breast cancer MDA-MB-231 cells by blocking various signaling pathways and regulating protein levels, thereby reducing TNF-α production and promoting apoptotic cell death.
DHMBA effectively inhibits the growth and metastasis of breast cancer cells, reduces bone microenvironment impairment, and minimizes side effects, providing a promising therapeutic strategy for breast cancer treatment.
Smart Images

Figure JP2024037697_02102025_PF_FP_ABST